Intermittent Theta-burst Transcranial Temporal Interference Stimulation focusing on the Putamen improves Motor Functions in Parkinson's Disease – A randomized, controlled Trial

Johannes Stalter MD[a,b,c*], Heiko Stecher PhD[d], Linda Bergmann MSc[e], Pedro Arizpe-Gómez MSc[e], Andreas Hein PhD[e], André Aleman PhD[c,f], Christoph S. Herrmann PhD [d,g], Karsten Witt MD[a,b,g]

a) Department of Neurology, Carl von Ossietzky University Oldenburg, Heiligengeisthöfe 4, 26121 Oldenburg, Germany

b) University Hospital of Neurology, Evangelical Hospital Oldenburg, Steinweg 13 – 17, 26122 Oldenburg, Germany

c) University of Groningen, Cognitive Neuroscience Center, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

d) Experimental Psychology Lab, Carl von Ossietzky University Oldenburg, Ammerländer Heerstraße 114 – 119, 26129 Oldenburg, Germany

e) Assistance Systems and Medical Device Technology, Carl von Ossietzky University Oldenburg, Ammerländer Heerstraße 114 – 119, 26129 Oldenburg, Germany

f) Faculty of Psychology and Neuroscience, Maastricht University, Universiteitssingle 40, 6229 ER Maastricht, The Netherlands

g) Center of Neurosensory Sciences, Carl von Ossietzky University Oldenburg, Ammerländer Heerstraße 114 – 119, 26129 Oldenburg, Germany

Words: 4000

Tables: 3

Figures: 4

References: 54

*Correspondence to: Johannes Stalter, MD

Johannes.stalter@uni-oldenburg.de

Dept. Of Neurology, University Oldenburg

Heiligengeisthöfe 4

26121 Oldenburg

Lower Saxony, Germany

This study is published as a preprint under https://doi.org/10.64898/2026.02.05.26345627 and has been presented at the International Brain Stimulation Conference 2025.

Abstract

Background: Transcranial temporal interference stimulation (tTIS) is a non-invasive method designed to target deep brain regions, such as the basal ganglia, without affecting overlying cortical areas. This study investigated intermittent theta-burst (iTBS) tTIS effects on symptom severity in Parkinson's disease (PD) and motor learning behavior, a condition associated with – among others – basal ganglia dysfunction. We hypothesized that iTBS-tTIS applied to the right putamen would alleviate PD symptoms and improve motor learning expressed by the contra-lateral hand.

Methods: This randomized, double-blinded, crossover trial included 19 PD patients (mean age 64 years, 14 males) and 19 age- and sex-matched healthy controls (mean age 68.6 years). Structural MRI data were obtained for each participant, and individualized electric field simulations were performed to predict field strength in the right putamen. The motor part of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) served as a primary outcome parameter, an alternating tapping task (aTT) and Motor learning assessed through a sequential finger tapping tasks (sFTT) were secondary outcome parameters.

Conclusion: ITBS-tTIS significantly reduced MDS-UPDRS motor scores in PD patients and the stimulation induced changes in motor performance correlated with the electric field strength in the targeted putamen region. No significant effects were found for motor performance or motor learning in either group. These findings indicate that iTBS-tTIS in general holds potential as a non-invasive approach for deep brain stimulation in PD.

Running title: tTIS in Parkinson's disease **Keywords:** Parkinson's disease; Neuromodulation; Temporal Interference Stimulation; Motor Learning; Deep Brain Stimulation

1 Introduction

Transcranial temporal interference stimulation (tTIS) is a newly developed technique to non-invasively stimulate deep brain regions without affecting the overlying cortex.[1] This method tackles the issues of the depth-focality tradeoff of “conventional” non-invasive brain stimulation techniques. tTIS is performed by applying two very-high frequency oscillations with slightly different frequencies (e.g. 2 kHz and 2.1 kHz) and a overlap in the region of interest (ROI), such as the basal ganglia (BG).[1] This way, the currents interfere resulting in a carrier frequency that is amplitude-modulated (AM) at the delta of both frequencies (envelope frequency). This AM-frequency then stimulates only the ROI (Figure 1A). For an overview of this technique, see recent literature.[2–5] By calculating the optimal electrode montage, the ROI can be individually optimized. tTIS has been proven safe and effective for stimulating deep brain regions in humans.[6–8]

In Parkinson’s disease (PD), disturbances in the motor network can be attributed to altered oscillations in anatomically segregated pathways that were targeted by electric stimulation as a treatment option.[9] PD is characterized by a loss of dopamine neurons in the substantia nigra (SN) with a consecutive dysfunction in the neural loops connecting the BG with cortical areas.[10] The motor dysfunctions are expressed by an increase of ß-oscillations with an anti-kinetic effect and a decrease of □-oscillations that diminishes their prokinetic effects.[11–13] The use of deep brain stimulation (DBS) in PD decreases the ß-power in the subthalamic nucleus (STN) in parallel with an improvement of motor symptoms but is limited by its invasiveness.[11,14,15] Non-invasive brain stimulation methods have not been sufficiently effective in PD, possibly due to their low focal intensity or limited stimulation depth. tTIS may overcome these disadvantages and can be applied with different stimulation settings, such as intermittent theta burst (iTBS) protocols that have been shown to elicit long lasting excitatory features.[16] tTIS therefore offers the potential to combine the positive effects of a cost-effective non-invasive therapy option with very little side-effects. Recently, it has been highlighted that there is a need for individualized electrical field simulation of non-invasive electrical stimulation to account for interindividual differences in anatomical variability, even more in pathologically altered brains.[17–21] To account for this, the electrical fields produced by tTIS can be simulated on a single subject level.[17]

In this study, we applied iTBS-tTIS in a randomized, double-blinded crossover study design in PD and healthy controls. Given its excitatory effect if iTBS on neuronal tissue (16), we hypothesized that iTBS-tTIS applied to the right putamen would enhance neural

communication at the entry point of the basal ganglia-thalamo-cortical loop system and reduce the severity of motor symptoms in PD patients . In an exploratory approach the strength of the simulated e-field in the right putamen is correlated with the clinical effect of the stimulation. Thus, our study tries to assess the efficiency and feasibility of using iTBS-tTIS in PD.

2 Materials and methods

2.1 Participants

Patients were recruited from the outpatient clinic at the University Hospital Oldenburg, Germany. Inclusion criteria were a clinical diagnosis of PD according to MDS-criteria.[22] Healthy participants were recruited via newspapers and matched by age and sex. All participants were right-handed (according to *Edinburgh Handedness Scale*), without a history of neurological or psychiatric diseases (except for PD in the PD group). Contraindications for MRI or electrical neurostimulation had to be absent. Further exclusion criteria were centrally acting medication and the cognitive deficits exceeding a Montreal Cognitive Assessment (MoCA) sum score lower than 18 points.[23] All participants gave written informed consent before inclusion in the study. Sample size was calculated using PASS (Version 20.0.9) based on previous results of studies using tTIS.[6] For our study, a power of 0.9 was specified, with an assumed effect size of 1.19 in a healthy study sample, a sample size of 18 participants for each group was calculated. The study was conducted according to the Declaration of Helsinki, was approved by the local ethics committee and preregistered in the German Registry of Clinical Trials (DRKS00030841).

2.2 Study design

The study was conducted in a randomized, double-blind cross-over design. PD patients were examined in medON. In the first session, a detailed clinical examination took place and MRI data were obtained for all participants. Participants and outcome assessors, were blinded throughout the whole study. The second session contained a baseline measurement of all experimental motor tasks described below, followed by the same order of tasks during the intervention. After stimulation a questionnaire about the adverse effects was given to

participants in each session. The third session was equivalent to the second session, with the corresponding condition (Figure 1C). Between sessions, a wash-out-phase of minimum 10 days was established.



Figure 1: A) The first two rows illustrate two high-frequency signals (2 kHz and 2.1 kHz). The third row presents their combination, resulting in an amplitude-modulated tTIS signal characterized by three distinct peaks. These peaks are highlighted in red in the fourth row, which depicts ten trains of three peaks each over a two-second period. The fifth row illustrates the intermittent theta-burst pattern, where each two-second train is followed by an eight-second pause. This pattern repeats throughout the stimulation, with a 30-second ramp-up and ramp-down period at the beginning and end of the stimulation, respectively. For illustration purposes, the signal is shown as zero whenever no amplitude modulation occurs. During these times, both signals were oscillating at 2 kHz. (B) Simulation of transcranial temporal interference stimulation using electrode placements at F5/C5 and F6/C6, with a peak-to-peak current of 2 mA for each electrode pair. The color bar indicates the voltage gradient (V/m), representing the current reaching deep brain regions. The crosshairs mark the putamen. This simulation was generated using the MATLAB © toolbox SimNIBS 4.0 (Saturnino et al., 2019). A transversal

section (upper figure) and a sagittal section (lower figure) are shown. (C) Study protocol: All participants were randomized (dice symbol) and double-blinded for assignment to the two study arms in a cross-over study design. (MRI = Magnetic Resonance Imaging; MDS-UPDRS III = Movement Disorder Society – Unified Parkinson's Disease Rating Scale motor part; sFTT = Sequential Finger Tapping Task, aTT = Alternating Tapping Task).

2.3 MRI data

Structural imaging was acquired using a 3.0 Tesla MRI system (Siemens Magnetom Prisma, Syngo MR E11, Siemens Medical Solutions, Erlangen, Germany) using a 64-channel head–neck-coil. A T1-weighted Magnetization Prepared Rapid Gradient Echo Sequence (MPRAGE) was obtained together with a T2-weighted scan and a fluid-attenuated inversion recovery (FLAIR) sequence.

2.4 Simulation

To simulate stimulation-effects, SimNIBS 4.1 was used.[1,24] Individual scans were segmented and conductivity of tissue type was assigned. Using these meshs, simulation on a single-subject level was computed. Simulations were run with an injected current of 2 mA peak-to-peak for electrode pairs positioned at F5-F6/CP5-CP6. Using the melb-atlas[25], we were able to simulate the electrical field in the right putamen adapted to the individual neuroanatomy of each participant (Figure 1B).

2.5 Stimulation

The stimulation was applied by two pairs of electrodes placed at F5-F6/CP5-CP6 attached to the scalp using ten20-paste (Weaver & Co, Aurora, CO, USA) with impedance below 10 kΩ. The right putamen was chosen since all participants self-reported being right-handed. We chose the intermittent theta-burst pattern as described by Wessel et al.[6] The theta-burst pattern is derived from hippocampal slices and was proven in TMS studies to have a beneficial effect on brain plasticity.[26] This pattern has already been proven to modulate behavioral outcomes when applied to the BG. We used a current-intensity of 2 mA (peak-to-peak) since this is below the recommended maximum current density in skin of 0.1 mA/cm^2 (= 2.5 mA zero-to-peak for 25cm^2 electrodes).[8]

Stimulations started and ended with a ramp-up and a ramp-down of 30 seconds. The stimulation signal consisted of two sinusoidal currents. One was always oscillating at 2 kHz, the other was switched between 2 and 2.1 kHz. If the two frequencies were different, this

resulted in an amplitude-modulated signal with a carrier frequency of 2.05 kHz (mean of the two frequencies) and a modulation frequency of 100 Hz (difference of the two frequencies). The switching of the frequency of the second current was chosen to result in periods of 30 ms – each containing three cycles of the 100 Hz amplitude-modulated oscillations (Figure 1A) targeting the putamen, followed by 170 ms with both signals oscillating at 2 kHz. This pattern is repeated over two seconds followed by a period with both signals oscillating at 2 kHz for eight seconds. This way, we mimicked a so-called Theta-Burst stimulation (5 Hz).[6] The duration of stimulation was 45 minutes. The stimulation signals were created with a Matlab (V*ersion R2022b*. Natick, Massachusetts: The MathWorks Inc.) script and were converted to voltage signals via a digital-to-analog converter (Ni-USB 6251, National Instruments, Austin, TX, USA). The voltage signal was delivered by two battery-driven, galvanically isolated constant current stimulators (Advanced DC Stimulator Plus, Neuroconn, Ilmenau, Germany).

2.6 Clinical and Motor Assessments and Outcomes

The primary objective was to investigate the effects of iTBI-tTIS on motor target variables. We considered the change in MDS-UPDRS Part III on the left-sided extremities to be the primary endpoint. Secondary endpoints include alternating tapping behavior evaluating proximal arm movements and finger sequence learning using the left hand.**[6]**

2.6.1 Clinical Assessment

For a clinical characterization, the MDS-UPDRS was used that included cognitive and affective domains (part I), management of activities of daily living (part II) and a detailed motor examination (part III) and motor complication such as dyskinesias and motor fluctuations (part IV).[22] The total score can reach a maximum of 132 points with higher scores indicating higher PD symptom severity. For each patient, the levodopa equivalent daily dosage (LEDD) was calculated according to the formulars of Joost et al. 2023.[27] The Montral Cognitive Assessment (MoCA) is used to assess the overall cognitive abilities over several domains.[28], [29] In addition we measured cognitive processing speed using the Symbol Digit Modalities Test (SDMT).[30] To screen for clinical relevant depression, we used the Beck Depression Inventory II, where a cut-off of 21 points indicates a clinical manifest depression.[31] All participants filled in the Edinburgh Handedness.[32] The side-effects of the stimulation were recorded based on structured self-reports of the participants.

The severity of the experienced sensations were asked on a scale from 0 to 4. After each session, the questionnaire had to be filled in.

2.6.2 Motor Assessments and Outcome Parameters

The primary outcome of this study was the changes in parkinsonian symptoms of the left extremities, defined as change in the MDS-UPDRS part III under stimulation compared against the sham effect in PD. The left side was chosen, as the right putamen was targeted with the stimulation montage.

The secondary outcome parameters focused on the amplitude and speed of movements of proximal sections of the left extremity, as well as motor learning. Performance of these motor tasks was measured at baseline and under real or sham stimulation condition. The alternating tapping task (aTT) measures the motor performance by counting the number of key presses that can be performed in five trials of 30 seconds intersected by four 30 seconds of rest periods. The keys for this task were 30 centimeters apart. The outcome of the aTT is the total number of key taps in 30 seconds across five alternative tapping runs, analyzed using a repeated measurement design. The sequential finger tapping task (sFTT) was used to assesses motor skill learning.[33] Participants were required to press four numeric keys on a computer keyboard with the fingers two to five of their left hand repeating a given five-element sequence (e.g. “4-2-3-1-2”, corresponding to the order “little finger– middle finger – ring finger – index finger – middle finger”) “as quickly and as accurately as possible” for a period of 30 seconds. Four different sequences were used in a counterbalanced order across the experimental runs. The numeric sequence is displayed on the screen in front of the participants at all times to minimize the working memory component of the task. Each block consisted of ten 30-second trails of sequential finger tapping followed a 30-second rest period. We selected an accuracy measure based on the quotient of correct finger taps in the given sequence divided by the total number of keystrokes achieved in 30 seconds. These quotients were then used for further statistical analysis.

2.7 Statistics

The data was analyzed and visualized using JASP Team (2025) (JASP [Version 0.95.4] and Matlab (V*ersion R2022b*. Natick, Massachusetts: The MathWorks Inc.). To analyze demographic data, a Wilcoxon rank test was used for non-normally distributed values. Motor

performance and motor learning was assessed with a linear mixed effects (LME) model, the variables group, condition, block and trial were used as fixed effects, the subject factor was inserted into the model as a random intercept. The MDS-UPDRS part III was analyzed by calculating the difference between baseline and sham or baseline and stim condition. Wilcoxon rank test was used to compare those values.

3 Results

3.1 Demographic and neuropsychological characteristics

19 PD patients and 19 healthy seniors participated and completed the study between October 2023 and June 2024. No significant differences were observed between groups in age or gender (see Table 1). Global cognitive competence as measured by the MoCA did not significantly differ between groups, while PD patients performed significantly lower in the SDMT (PD 36.4 ± 11.50 vs. HC 47.0 ± 8.44, p=0.002). No participants were screened as demented according to a MoCA Score < 18 points. BDI II scores also did not significantly differ between PD patients and HC. No participant was classified as depressed according to a BDI II score > 21 points. None of the participants stated to be a smoker and all participants were right-handed according to the *Edinburgh Handedness Scale.* The mean time period between the two stimulation sessions was 10.31 days (HC mean 8.1 min/max 6/16, PD mean 10.58 min/max 6/15) across both groups.

Further clinical data of the PD patient group are given in Table 1. The MDS-UPDRS part III revealed a mean of 19.26 (± 9.26) points. With means at the first session of 19.26 (± 8.89) and at the second session of 17.42 (± 8.84) (p = 0.21), there was no significant difference between both stimulation sessions. The average Hoehn & Yahr stage was 2.3 (SD=0.4).

Eleven patients (57.89%) showed the left side to be the dominantly affected side, while eight patients (42.11%) were more impaired on the right side. The mean disease duration was 6.26 years (SD = 4.43). For the LEDD a mean of 494.93 mg (SD = 309.76) was calculated.

Table 1: Baseline and clinical characteristics

	PD group	HC group	p-value
Age (years, mean, SD)	64.70 (9.27)	68.60 (6.26)	0.05
Sex (m/f)	13/6	10/9	0.05

Handedness (r/l)	19/0	19/0	
Most affected side (right/left)	8/11	-	
MoCA (mean, SD)	22.90 (2.65)	22.6 (1.71)	0.05
SMDT (mean, SD)	36.4 (11.50)	47.0 (8.44)	0.002
BDI (mean, SD)	7.78 (6.15)	5.11 (4.18)	0.05

Clinical data of the PD group

	N	Minimum	Maximum	Mean	Std. Dev.
UPDRS_I	19	0	18	6.94	5.14
UPDRS_II	19	0	16	8.36	4.51
UPDRS_III	19	7	41	19.0	9.26
UPDRS_IV	19	0	8	1.26	2.077

SD = Standard deviation; PD = Parkinson's disease; HC = Healthy controls; m= male; f = female; MoCA = Montreal Cognitive Assessment; SDMT= Symbol Digit Modality Test; BDI = Becks Depression Inventory; MDS-UPDRS = Movement Disorder Society – Unified Parkinson's Diseases Rating Scale

3.2 Clinical Outcomes

3.2.1 MDS-UPDRS

The change of the sum score of the MDS-UPDRS left sided items of the extremities between pre to during real stimulation and the pre to during sham condition revealed a significant greater improvement of the real stimulation (W = 30.5, p = 0.015, r = 0.49, Mann-Whitney-U test). Table 2 shows the changes for the MDS-UPDRS part III and the different sub-scores for bradykinesia, tremor and rigidity of the left extremities. Due to the low number of items within the sub-scores, no further analysis of the sub-scores were conducted.

Table 2 Results of the left-sided MDS-UPDRS part III

	pre stim	*during stim*	*change*	*pre sham*	*during sham*	*change*	*p-value*
Total (SD)	3.33 (2.92)	2.22 (1.57)	-1.11 (0.73)	1.72 (1.78)	2.88 (2.01)	1.16 (0.51)	0.015
Bradykinesia (SD)	3.77 (2.05)	3.50 (2.31)	-0.27 (0.47)	3.66 (2.08)	3.72 (1.65)	0.06 (0.30)	
Tremor (SD)	0.88 (1.29)	0.76 (1.04)	-0.12 (0.21)	0.88 (1.02)	0.47 (0.51)	-0.41 (0.24)	
Rigidity (SD)	2.44 (1.90)	1.88 (1.80)	-0.56 (0.33)	1.72 (1.89)	1.88 (1.86)	0.16 (0.31)	

3.2.2 Simulation results

The calculation of the mean e-field strength in the right putamen showed a comparable e-field of both groups (PD: 0.226 V/m (SD = 0.022) vs. HC: 0.242 V/m (SD = 0.031), p = 0.07). Pearson correlation analysis revealed a significant negative correlation between the calculated e-field and the improvement of motor function (p = 0.023, slope = - 78,2151 [MDS-UPDRS points / V]) (Figure 2).



Figure 2: Correlation of the calculated change in the left-sided MDS-UPDRS and the simulated e-field of the right putamen. Blue points indicate individual patient data; the red line shows the regression line. There is a significant correlation between the mean e-field and the MDS-UPDRS. (MDS-UPDRS = Movement Disorder Society – Unified Parkinson's Disease Rating Scale.)

3.3 Alternating Tapping Task

The LME applied to the aTT data showed significant effects for trial (chi^2 = 13.987, p = 0.007), block (chi^2 = 104.916, p < 0.001) and stim (chi^2 = 64.322, p < 0.001) while group

presented only a trend ($chi^2 = 3.087$, $p = 0.079$). The interaction block x stim ($chi^2 = 50.825$, $p < 0.001$), block x group ($chi^2 = 48.761$, $p < 0.001$) and stim x group ($chi^2 = 51.066$, $p < 0.001$) were significant. Bonferroni adjusted post-hoc tests revealed a significant stimulation effect in the HC group compared to sham (estimate = 27.179; SE = 2.835; df = ∞; 95% CI 21.622 – 32.736; z = 9.586; p < .001), as well as a corresponding greater stimulation effect for HC than for PD (estimate = -24.846; SE = 4.065; df = ∞; 95% CI -32.813 – -16.878; z = -6.112; p < 0.001). It is noteworthy that the baseline in the tTIS session for the HC group was significantly lower than the baseline in the sham session. Therefore, most likely the significant stimulation effect was driven by a poor performance in the HC group. No significant effects were found for the PD group (figure 3).



Figure 3: Hits are defined as key presses on two different buttons. There was a significant improvement between the baseline and tTIS in the control group. No significant change was observed in the Parkinson's disease group. HC = Healthy controls; PD = Parkinson's disease.

3.4 Sequential Finger Tapping Task

The linear mixed effect model (LME) showed significant effects of block ($chi^2 = 10.967$, $p < 0.001$), stim ($chi^2 = 11.929$, $p < 0.001$), Group ($chi^2 = 7.823$, $p = 0.005$) and trial ($chi^2 = 31.304$, $p < 0.001$). Investigating the interactions, stim x group were significant ($chi^2 = 10.342$, $p = 0.001$). The Bonferroni adjusted post-hoc tests however did not reach a significant level for either group (figure 4).

Figure



Figure 4: Results of the Sequential Finger Tapping Task. Upper panel: Sham sessions for both groups. Lower panel shows the data of the real stimulation tTIS sessions. Lines represent the marginal means while dots and triangles show individual data. Mean accuracy is calculated as the results of key presses within a correct sequence with all key presses of the trial. Again, No significant effects of real or sham stimulation were observed in either group. HC = Healthy controls; PD = Parkinson's disease.

3.5 Side effects of non-invasive neurostimulation

No severe side effects were reported in any group for any the condition. Table 3 shows the reported side effects and how often they were reported. Due to the low number of total reported side-effects and the almost even distribution between sham and stim conditions, no statistical analysis was performed.

Table 3: Described side effects during and after transcranial temporal interference stimulation

Symptom	Total_count	Ratio sham condition	Ratio stim condition
Headache	4	0.75	0.25
Neck pain	3	0.33	0.66
Local pain	2	0.5	0.5
Dysesthesia	5	0.2	0.8
Burning sensation	4	0.5	0.5
Local warming	4	0.25	0.75
Redness	13	0.46	0.53
Fatigue	19	0.47	0.52
Concentration problems	6	0.33	0.66

Mood changes	1	0	1

4 Discussion

In this study, iTBS-tTIS was combined with clinical examinations and motor tasks in a PD group and a control group. A short stimulation of the putamen was able to improve the online MDS-UPDRS score as a clinical marker of symptom severity. Stimulation-induced changes in MDS-UPDRS part III correlated significantly with the simulated e-field in the right putamen. tTIS had no significant effect on motor-learning behavior or tapping behavior, neither in the HC nor in the PD group. No severe adverse side-effects were observed.

Baseline characteristics show a well-matched selection of participants, with the PD data suggesting a clinically mildly affected group with moderate LEDD and short disease duration. The influence of cognitive impairment as a driver for differences in the performance was ruled out. The results of the SDMT in turn showed an impairment of the processing speed as expected in PD. Since the cognitive processing speed can have an influence on the motor speed, especially in tapping tasks in Parkinson's disease, these results match with the generally lower scores in the tasks used in this study.[34]

Mild adverse side effect that occurred were mostly of very short duration and lasted the longest until a few minutes after stimulation. The distribution between sham and stim condition was rather even, given the small number of reported cases.

Improvement of Parkinson's disease symptoms

We were able to enhance the performance of PD patients in the MDS-UPDRS by using high gamma frequency with iTBS pattern over a short period of time. When correlating the improvement in the UPDRS with the simulated e-field in the ROI, a significant correlation could be shown, i.e. higher simulated e-fields were shown in participants with greater improvement under stimulation. This may provide a causal connection between the experimental stimulation and the online clinical effects on patients.

One of the hallmarks of PD is the impaired movement, especially a slowing down, a reduction of the movement and irregularities in timing and a sequence effect (progressive reduction in velocity/amplitude over time) as measured in the MDS-UPDRS.[35,36][37] Typically, these parameters are decreasing more over the examination time. Dopaminergic dysfunction in PD is particularly pronounced in the SN, pars compacta where neurons are projecting into the putamen.[38] [39] In the pathophysiological model of PD, due to the

degeneration of dopaminergic neurons in the SN the inhibiting effect of the putamen to the GPi is decreased. In parallel, the inhibition of the STN decreases. These two mechanisms lead to an extensive excitation of the GPi, which in turn functions as the “exit nucleus” of the BG loop.[40,41] Conventional DBS is using the STN as the target region, i.e. changing the output of the BG loop.[42] By choosing the “entrance” of the BG loop, i.e. the putamen as target region, the BG system in general can be altered in two ways. By facilitating the effects of the putamen, the direct pathway, which promotes movement, is enhanced while the indirect pathway, which inhibits movement, is even more suppressed. Huang et al. showed that the effect of iTBS on the central nervous system emerges right after starting the stimulation.[43] In addition, it is thought that not only pathological frequencies but also pathological neuronal firing patterns are phenomena closely connected with PD.[44] Therefore it can be assumed that changing the entrance of the BG loop into a more physiological way, the effects on the following structures are not only changing the firing rate but also modulate the firing pattern. This is of special interest when considering the other loops of the BG, namely the limbic and the cognitive loop.

By improving patients in this early disease stage with tTIS, it opens the therapy approach even for patients in earlier stages of the disease even before motor complications occur. The online improvement of motor symptoms in Parkinson’s disease using tTIS in the region of the putamen with a plasticity modulating stimulation paradigm can be therefore interpreted as a proof of feasibility and therefore paves to way for this technique as a new treatment principal. Only few studies investigated the effects of tTIS in Parkinson’s disease.[45–50] Those other studies chose a stimulation paradigm closely related to the paradigm of conventional DBS, using tTIS to disrupt neuronal firing and therefore improve motor symptoms in Parkinson’s disease. By using an intermitted theta burst approach, we used neuronal excitatory and plasticity effects to modulate PD symptoms.

Simulation of applied e-fields

Using an individualized approach to simulate the electrical fields for each individual, not only were individual differences taken into account, but also differences related to the pathological changes, such as atrophy with a consecutive larger cerebrospinal fluid volume with higher shunting effects, during the course of the neurodegenerative disease. Interestingly, there are no significant differences between the mean values when both groups are compared. Since a threshold of 0.2 V/m is thought to be necessary to sufficiently stimulate neurons on a subthreshold level, the individual e-field data for both groups show the potential of tTIS to

stimulate deep brain regions.[51,52] The comparability of both groups regarding the individualized e-fields might be explained by the short disease duration of the PD group. To our knowledge, no study investigated this so far and this finding adds valuable insights into the question of how individualized tTIS should be performed in a clinical setting.

Effects on motor learning

The motor learning behavior of controls and PD patients could not be improved in this study. The missing improvement in motor learning in the PD group could be explained by a theory raised by Seidler et al.[53] According to this hypothesis, the learned motor behavior needs to be translated into the movement pattern, causing a potential difference between motor learning and motor performance. Meaning if the motor execution is impaired, the motor learning takes place but cannot be executed (learning-performance-dissociation). Since the motor execution is impaired in Parkinson's disease, this could be one part of a potential explanation for the missing improvement. Another part may be strong placebo effect that is typical in PD and diminishes potential stimulation effects.[54] Besides these disease-specific reasons, there are additional potential explanations which need to be considered for both groups. For tTIS, there is no established dose-dependency known, representing potential reason related to the stimulation time. Furthermore, there seems to be a ceiling effect which has prevented the stimulation changes from being large enough to reach significance between groups or conditions.

Effects on alternative tapping

Like the motor learning behavior, the motor performance showed a significant effect for the HC group. This effect seems to be promoted mainly by the lower baseline performance in the group at the stimulation session. Considering the similar pattern across all conditions, it seems likely that there was a strong ceiling effect in the behavioral data. Given the relatively mild disease stage of the PD cohort, proximal movements may have been insufficiently sensitive to subtle changes in bradykinesia. This can also partly explain the difference between the clinical and the behavioral results. In addition, the limitations for the results of the sFTT apply to this task as well.

Limitations

There was a certain heterogeneity in the PD group, mostly regarding the MDS-UPDRS part III and the affected side which might have limited the effects in the presented study. In

addition to this, the stimulation took place mostly in the medication ON-state, which might have masked stimulation effects. A relatively short stimulation duration as well as low amplitude may be considered as stimulation-related limitations.

Future Directions

We were able to prove the feasibility and short-term clinical impact of iTBS-tTIS leading to its investigation as a potential treatment option. Therefore, this cost-effective and safe method opens a new field of neuro-enhancement and techniques to understand cognitive functioning pathologically alters states in deeper brain regions. Together with the clinically measured improvement in PD symptoms it can be interpreted as a proof for its feasibility and its potential as a new therapeutical approach.

In future studies, larger groups of more severely affected patients should be investigated. Additionally, investigations regarding the dose-dependency and potential after-effects should take place. Since no severe adverse side-effects were reported in our study, which is in line with other experiments, one could think of higher stimulation currents to further improve the effects of non-invasive deep brain stimulation.[7]

5 Data availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

6 Funding

The study was partly funded by the German Research Council (DFG), under the Research Training Group Neuromodulation of Motor and Cognitive Function in Brain Health and Disease (RTG 2783).

7 Author contributions

Conceptualization: JS, AA, CSH, KW; Data curation: JS; Formal analysis: JS, HS, LB, PAG, AH, CSH, KW; Funding acquisition: JS, AA, CSH, KW; Methodology: JS; HS, LB, PAG, AH, AA, CSH, KW; Project administration: JS; Resources: JS; AA, CSH, KW; Supervision: AA, Ah, CSH, KW; Writing: JS, CSH, KW; Writing editing: HS, LB, PAG, AA, CSH, KW

8 Competing interests

The authors declare no conflict of interest relevant to the presented work. The following financial interests/personal relationships are declared: CSH holds a patent on brain stimulation. JS received speaker fees from Roche Pharma. KW received travel expense reimbursement and speaker fees from BIAL, Stadapharma, Eisai and Project funding from the DFG as well as from the state of Lower Saxony. HS, LB, PAG, AH, AA declare no competing interests.

9 References

[1] Grossman N, Bono D, Dedic N, Kodandaramaiah SB, Rudenko A, Suk HJ, et al. Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields. Cell 2017;169:1029-1041.e16. https://doi.org/10.1016/j.cell.2017.05.024.

[2] Stalter J, Aleman A, Witt K, Herrmann CS. Scientific Methods to Enhance Cognitive Performance and Brain Plasticity: Transcranial Alternating Current/Temporal Interference Stimulation. In: Barbey A, editor. The Oxford Handbook of Cognitive Enhancement and Brain Plasticity, Oxford University Press; 2025. https://doi.org/10.1093/oxfordhb/9780197677131.001.0001.

[3] Hummel FC, Wessel MJ. Non-invasive deep brain stimulation: interventional targeting of deep brain areas in neurological disorders. Nat Rev Neurol 2024;20:451–2. https://doi.org/10.1038/S41582-024-00990-8.

[4] Luff CE, Dzialecka P, Acerbo E, Williamson A, Grossman N. Pulse-width modulated temporal interference (PWM-TI) brain stimulation. Brain Stimul 2024;17:92–103. https://doi.org/10.1016/J.BRS.2023.12.010.

[5] Demchenko I, Tailor I, Chegini S, Yu H, Gholamali Nezhad F, Rueda A, et al. Human Applications of Transcranial Temporal Interference Stimulation: A Systematic Review 2025. https://doi.org/10.1101/2025.05.16.25327804.

[6] Wessel MJ, Beanato E, Popa T, Windel F, Vassiliadis P, Menoud P, et al. Noninvasive theta-burst stimulation of the human striatum enhances striatal activity and motor skill learning. Nature Neuroscience 2023 2023:1–12. https://doi.org/10.1038/s41593-023-01457-7.

[7] Vassiliadis P, Stiennon E, Windel F, Wessel MJ, Beanato E, Hummel FC. Safety, tolerability and blinding efficiency of non-invasive deep transcranial temporal interference stimulation: first experience from more than 250 sessions. J Neural Eng 2024;21. https://doi.org/10.1088/1741-2552/AD2D32.

[8] von Conta J, Kasten FH, Schellhorn K, Ćurčić-Blake B, Aleman A, Herrmann CS. Benchmarking the effects of transcranial temporal interference stimulation (tTIS) in humans. Cortex 2022;154:299–310. https://doi.org/https://doi.org/10.1016/j.cortex.2022.05.017.

[9] Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896–908. https://doi.org/10.1056/NEJMoa060281.

[10] Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 2010;6:487–98. https://doi.org/10.1038/nrneurol.2010.111.

[11] Doyle LMF, Kühn AA, Hariz M, Kupsch A, Schneider G-H, Brown P. Levodopa-induced modulation of subthalamic beta oscillations during self-paced movements in patients with Parkinson's disease. Eur J Neurosci 2005;21:1403–12. https://doi.org/10.1111/j.1460-9568.2005.03969.x.

[12] Tinkhauser G, Pogosyan A, Tan H, Herz DM, Kühn AA, Brown P. Beta burst dynamics in Parkinson's disease OFF and ON dopaminergic medication. Brain 2017;140:2968–81. https://doi.org/10.1093/brain/awx252.

[13] Neumann W-J, Steiner LA, Milosevic L. Neurophysiological mechanisms of deep brain stimulation across spatiotemporal resolutions. Brain 2023;146:4456–68. https://doi.org/10.1093/brain/awad239.

[14] Kühn AA, Kempf F, Brücke C, Gaynor Doyle L, Martinez-Torres I, Pogosyan A, et al. High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta

activity in patients with Parkinson's disease in parallel with improvement in motor performance. J Neurosci 2008;28:6165–73. https://doi.org/10.1523/JNEUROSCI.0282-08.2008.

[15] Köhler RM, Binns TS, Merk T, Zhu G, Yin Z, Zhao B, et al. Dopamine and deep brain stimulation accelerate the neural dynamics of volitional action in Parkinson's disease. Brain 2024;147:3358–69. https://doi.org/10.1093/brain/awae219.

[16] Kricheldorff J, Göke K, Kiebs M, Kasten FH, Herrmann CS, Witt K, et al. Evidence of Neuroplastic Changes after Transcranial Magnetic, Electric, and Deep Brain Stimulation. Brain Sci 2022;12. https://doi.org/10.3390/brainsci12070929.

[17] Saturnino GB, Puonti O, Nielsen JD, Antonenko D, Madsen KH, Thielscher A. SimNIBS 2.1: A Comprehensive Pipeline for Individualized Electric Field Modelling for Transcranial Brain Stimulation. Brain and Human Body Modeling: Computational Human Modeling at EMBC 2018 2019:3–25. https://doi.org/10.1007/978-3-030-21293-3_1.

[18] Kasten FH, Duecker K, Maack MC, Meiser A, Herrmann CS. Integrating electric field modeling and neuroimaging to explain inter-individual variability of tACS effects. Nature Communications 2019 10:1 2019;10:1–11. https://doi.org/10.1038/s41467-019-13417-6.

[19] von Conta J, Kasten FH, Ćurčić-Blake B, Aleman A, Thielscher A, Herrmann CS. Interindividual variability of electric fields during transcranial temporal interference stimulation (tTIS). Sci Rep 2021;11:20357. https://doi.org/10.1038/s41598-021-99749-0.

[20] Haber I, Jackson A, Thielscher A, Hai A, Tononi G. TI-Toolbox: An open-source software for temporal interference stimulation research. Brain Stimul 2026;19. https://doi.org/10.1016/j.brs.2025.103016.

[21] Brahma T, Guillen A, Moreno J, Datta A, Huang Y. On the need of individually optimizing temporal interference stimulation of human brains due to inter-individual variability. Brain Stimul 2025;18:1373–88. https://doi.org/10.1016/j.brs.2025.07.006.

[22] Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–601. https://doi.org/10.1002/MDS.26424.

[23] Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73:1738. https://doi.org/10.1212/WNL.0B013E3181C34B47.

[24] Thielscher A, Antunes A, Saturnino GB. Field modeling for transcranial magnetic stimulation: A useful tool to understand the physiological effects of TMS? Annu Int Conf IEEE Eng Med Biol Soc 2015;2015:222–5. https://doi.org/10.1109/EMBC.2015.7318340.

[25] Tian Y, Margulies DS, Breakspear M, Zalesky A. Topographic organization of the human subcortex unveiled with functional connectivity gradients. Nature Neuroscience 2020 23:11 2020;23:1421–32. https://doi.org/10.1038/s41593-020-00711-6.

[26] Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron 2005;45:201–6. https://doi.org/10.1016/j.neuron.2004.12.033.

[27] Jost ST, Kaldenbach MA, Antonini A, Martinez-Martin P, Timmermann L, Odin P, et al. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. Movement Disorders 2023;38:1236–52. https://doi.org/10.1002/mds.29410.

[28] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive

impairment. J Am Geriatr Soc 2005;53:695–9. https://doi.org/10.1111/j.1532-5415.2005.53221.x.
[29] Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73:1738–45. https://doi.org/10.1212/WNL.0B013E3181C34B47.
[30] Smith A. Symbol Digit Modalities Test (Revised). Western Psychological Services 1973. https://doi.org/https://doi.org/10.1037/t27513-000.
[31] Hautzinger M, Keller F, Kühner C. Beck Depressions-Inventar (BDI-II). Revision. Nervenarzt 2006;62:689–96.
[32] Veale JF. Edinburgh Handedness Inventory - Short Form: a revised version based on confirmatory factor analysis. Laterality 2014;19:164–77. https://doi.org/10.1080/1357650X.2013.783045.
[33] Walker MP, Brakefield T, Morgan A, Hobson JA, Stickgold R. Practice with sleep makes perfect: Sleep-dependent motor skill learning. Neuron 2002;35:205–11. https://doi.org/10.1016/S0896-6273(02)00746-8.
[34] Menon V, Hegde S, Pratyusha P, Kamble N, Yadav R, Bhattacharya A, et al. Motor Speed Matters! Cognitive Profile of Parkinson's Disease Patients with and without Deficits in Motor Speed. Neurol India 2021;69:604–8. https://doi.org/10.4103/0028-3886.317232.
[35] Lees AJ, Hardy J, Revesz T. Parkinson's disease. The Lancet 2009;373:2055–66. https://doi.org/10.1016/S0140-6736(09)60492-X.
[36] Bologna M, Espay AJ, Fasano A, Paparella G, Hallett M, Berardelli A. Redefining Bradykinesia. Movement Disorders 2023;38:551–7. https://doi.org/10.1002/MDS.29362.
[37] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders 2008;23:2129–70. https://doi.org/10.1002/mds.22340.
[38] Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960;38:1236–9. https://doi.org/10.1007/BF01485901.
[39] Fahn S, Sulzer D. Neurodegeneration and Neuroprotection in Parkinson Disease. NeuroRx 2004;1:139. https://doi.org/10.1602/NEURORX.1.1.139.
[40] Rivlin-Etzion M, Marmor O, Heimer G, Raz A, Nini A, Bergman H. Basal ganglia oscillations and pathophysiology of movement disorders. Curr Opin Neurobiol 2006;16:629–37. https://doi.org/10.1016/j.conb.2006.10.002.
[41] Kravitz A V, Freeze BS, Parker PRL, Kay K, Thwin MT, Deisseroth K, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010;466:622–6. https://doi.org/10.1038/nature09159.
[42] Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson's Disease with Early Motor Complications. New England Journal of Medicine 2013;368:2037–8. https://doi.org/10.1056/nejmc1303485.
[43] Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron 2005;45:201–6. https://doi.org/10.1016/j.neuron.2004.12.033.
[44] Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci 2007;30:357–64. https://doi.org/10.1016/J.TINS.2007.05.004.

[45] Yang C, Xu Y, Feng X, Wang B, Du Y, Wang K, et al. Transcranial Temporal Interference Stimulation of the Right Globus Pallidus in Parkinson's Disease. Movement Disorders 2025;40:1–9. https://doi.org/10.1002/MDS.29967.
[46] Yang C, Xu Y, Du Y, Shen X, Li T, Chen N, et al. Transcranial Temporal Interference Subthalamic Stimulation for Treating Motor Symptoms in Parkinson's Disease: A Pilot Study. Brain Stimul 2024;17:1250–2. https://doi.org/10.1016/J.BRS.2024.10.012.
[47] Lamoš M, Bočková M, Missey F, Lubrano C, de Araújo e Silva M, Trajlínek J, et al. Noninvasive Temporal Interference Stimulation of the Subthalamic Nucleus in Parkinson's Disease Reduces Beta Activity. Movement Disorders 2025;40:1051–60. https://doi.org/10.1002/MDS.30134.
[48] Li T, Yang C, Xu Y, Du Y, Shen X, Zhou J, et al. Transcranial temporal interference stimulation of the globus pallidus internus ameliorates gait variability in early- to mid-stage Parkinson's disease: A pilot study. Brain Stimul 2026;19. https://doi.org/10.1016/j.brs.2025.103007.
[49] Yang C, Xu Y, Du Y, Shen X, Li T, Chen N, et al. Transcranial Temporal Interference STN Stimulation Alleviates Motor Symptoms in Parkinson's Disease A Pilot Randomized Controlled Study. SSRN 2025;Preprint. https://doi.org/https://dx.doi.org/10.2139/ssrn.5677263.
[50] Williamson A, Missey F, Acerbo E, Lamoš M, Bočková M, Neufeld E, et al. Clinical Results of Non-invasive Deep Brain Stimulation in Epilepsy and Parkinson's patients using Temporal Interference. Brain Stimul 2025;18:208–607. https://doi.org/10.1016/j.brs.2024.12.018.
[51] Louviot S, Tyvaert L, Maillard LG, Colnat-Coulbois S, Dmochowski J, Koessler L. Transcranial Electrical Stimulation generates electric fields in deep human brain structures. Brain Stimul 2022;15:1–12. https://doi.org/10.1016/J.BRS.2021.11.001.
[52] Huang Y, Liu AA, Lafon B, Friedman D, Dayan M, Wang X, et al. Measurements and models of electric fields in the in vivo human brain during transcranial electric stimulation. Elife 2017;6. https://doi.org/10.7554/ELIFE.18834.
[53] Seidler RD, Purushotham A, Kim SG, U□urbil K, Willingham D, Ashe J. Cerebellum activation associated with performance change but not motor learning. Science 2002;296:2043–6. https://doi.org/10.1126/science.1068524.
[54] Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. Movement Disorders 2018;33:1213–27. https://doi.org/10.1002/mds.27438.